Core Viewpoint - Dongfang Ocean announced that its major shareholder, Guoyuan Fund, reduced its stake in the company by 19,580,000 shares, representing 1% of the total share capital, as part of a previously disclosed share reduction plan [2]. Summary by Relevant Sections - **Shareholder Activity** - Guoyuan Fund, a major shareholder holding over 5% of Dongfang Ocean, reduced its holdings by 19,481,000 shares through block trading on September 23, 2025, and an additional 99,000 shares through centralized bidding on November 10, 2025 [2]. - After the reduction, Guoyuan Fund's total shareholding decreased from 8.00% to 7.00%, with a remaining share count of 137,155,727 shares [2].

证券代码：002086 证券简称：东方海洋 公告编号：2025-061 山东东方海洋科技股份有限公司 关于持股 5%以上股东减持股份触及 1%整数倍的公告 国元基金保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 深圳前海国元私募证券基金管理有限公司－国元价值精选一号私募证券投 资基金（以下简称"国元基金"）为持有山东东方海洋科技股份有限公司（以下简 称"公司"）5%以上股份的大股东，公司近日获悉，国元基金于 2025 年 9 月 23 日通过大宗交易方式减持公司股份 19,481,000 股，于 2025 年 11 月 10 日通过集 中竞价方式减持公司股份 99,000 股，共计减持 19,580,000 股，占公司总股本的 1%（以下简称"本次减持"）。本次减持后，国元基金持有公司股份 137,155,727 股，持股比例由 8.00%变更为 7.00%，变动触及 1%的整数倍。本次减持属于持 股 5%以上股东实施前期已披露的股份减持计划。现将具体情况公告如下： 1 1．基本情况 信息披露义务人 深圳 ...

Core Viewpoint - The major shareholder, Guoyuan Fund, has reduced its stake in Dongfang Ocean by 19.58 million shares, representing 1% of the total share capital, which decreases its ownership from 8% to 7% [1] Summary by Relevant Sections - **Shareholder Actions** - Guoyuan Fund executed share reductions on September 23 and November 10, 2025, through block trading and centralized bidding methods [1] - The reduction is part of a previously disclosed plan and remains within the allowed reduction limits [1] - **Impact on Company** - The share reduction will not lead to a change in company control [1] - The operational aspects of the company remain unaffected by this reduction [1]

Core Viewpoint - The company reported a significant decline in net profit and revenue for the third quarter, primarily due to decreased gross margins in its main product lines, particularly sea cucumbers and testing kits [5]. Financial Performance - The net profit attributable to shareholders decreased by 51.43% year-on-year, mainly due to a decline in gross margin [5]. - Revenue from sea cucumbers dropped by 62.56%, attributed to reduced sales and a shift in production strategy [5]. - Revenue from testing kits fell by 76.13%, largely due to the loss of a significant order from a key customer [5]. - The net profit excluding non-recurring gains and losses decreased by 38.31% year-on-year, reflecting similar trends as the overall net profit [5]. - The net cash flow from operating activities increased by 37.99% compared to the same period last year, driven by higher sales in the seafood processing business [5]. Shareholder Information - The company confirmed that there were no changes in the number of shareholders or significant shareholders participating in stock lending activities [6]. Product Development - The company's wholly-owned subsidiary, Aiveke Biotechnology Co., Ltd., received regulatory approval for a new medical device, the NT-proBNP testing kit, which is expected to enhance its product line in clinical diagnostics [10][11]. - The impact of this new product on the company's performance remains uncertain, as it has not yet commenced production and its market performance will depend on various factors [9][11].

Core Viewpoint - Dongfang Ocean (002086.SZ) reported a decline in revenue and a significant net loss for the first three quarters of 2025 [1] Financial Performance - The company achieved an operating revenue of 246 million yuan, representing a year-on-year decrease of 0.78% [1] - The net loss attributable to shareholders of the listed company was 105 million yuan [1] - The net loss attributable to shareholders, after deducting non-recurring gains and losses, was 111 million yuan [1]

Core Insights - The company reported a revenue of 246 million yuan for the first three quarters of 2025, a year-on-year decrease of 0.78% [1] - The net profit attributable to shareholders was -105 million yuan, down 51.43% year-on-year, with a basic earnings per share of -0.05 yuan [1] - The gross margin for the first three quarters was 0.35%, a decline of 9.96 percentage points compared to the previous year [1] Financial Performance - The company’s net profit margin was -43.22%, a decrease of 14.87 percentage points year-on-year [1] - In Q3 2025, the gross margin was 2.54%, down 1.43 percentage points year-on-year but up 16.19 percentage points quarter-on-quarter [1] - The net profit margin for Q3 was -38.42%, a decline of 7.47 percentage points year-on-year, but an increase of 22.78 percentage points from the previous quarter [1] Expense Analysis - Total operating expenses for the period were 93.48 million yuan, a decrease of 3.68 million yuan year-on-year [2] - The expense ratio was 38.00%, down 1.19 percentage points from the previous year [2] - Sales expenses increased by 4.19%, while management and R&D expenses decreased by 7.57% and 13.31%, respectively [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 72,500, a decrease of 5,187 or 6.68% from the previous half [2] - The average market value per shareholder decreased from 71,400 yuan to 70,000 yuan, a decline of 1.93% [2] Company Overview - The company, Shandong Oriental Ocean Technology Co., Ltd., is located in Yantai, Shandong Province, and was established on December 19, 2001 [2] - The main business activities include seawater seed breeding, aquaculture, seafood processing, biotechnology, bonded warehousing logistics, and the R&D, production, and sales of in vitro diagnostic reagents [2] - The revenue composition includes processing of raw materials (47.77%), domestic trade (11.46%), and other segments [2] Industry Classification - The company belongs to the pharmaceutical and biological industry, specifically in the medical device and in vitro diagnostic sector [3] - It is associated with concepts such as gene sequencing, antigen testing, private hospitals, and pre-prepared dishes [3]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1. 艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批上市的 氨基末端脑利钠肽前体（NT-proBNP）测定试剂盒（荧光免疫层析法）的投产及 对公司业绩的后续影响具有不确定性，请广大投资者注意投资风险。 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 证券代码：002086 证券简称：东方海洋 公告编号：2025-060 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 一、产品信息 1、氨基末端脑利钠肽前体（NT-proBNP）测定试剂盒（荧光免疫层析法） | 产品名称 | 氨基末端脑利钠肽前体（NT-proBNP）测定试剂盒（荧光免疫层析法） | | | | | | | | --- | --- | --- | --- | --- | --- | --- | -- ...

Core Viewpoint - Dongfang Ocean reported a decline in both revenue and net profit for the third quarter and the first three quarters of the year, indicating ongoing financial challenges [1] Financial Performance - The third quarter revenue was 89.93 million yuan, a year-on-year decrease of 2.67% [1] - The net profit for the third quarter was a loss of 34.39 million yuan, representing a decline of 22.23% [1] - For the first three quarters, the total revenue was 246 million yuan, down 0.78% year-on-year [1] - The net profit for the first three quarters showed a loss of 105 million yuan, which is a significant decline of 51.43% [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥89,926,823.81, a decrease of 2.67% compared to the same period last year[5]. - The net profit attributable to shareholders decreased by 22.23% year-on-year, amounting to -¥34,388,630.64[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 11.41%, totaling -¥37,113,547.34[5]. - Total operating revenue for the current period is $245.97 million, a decrease of 0.78% from $247.91 million in the previous period[18]. - Net profit for the current period is -$106.31 million, compared to -$70.30 million in the previous period, indicating a significant increase in losses[19]. - Basic and diluted earnings per share for the current period are both -$0.05, compared to -$0.04 in the previous period[19]. Cash Flow - The cash flow from operating activities showed a net increase of 37.99%, with a total of -¥107,354,267.38 year-to-date[5][9]. - The net cash flow from operating activities is -$107.35 million, an improvement from -$173.12 million in the previous period[20]. - The company received cash from operating activities totaling $266.26 million, slightly up from $265.35 million in the previous period[21]. - The company reported a net cash outflow from investing activities of -$2.23 million, an improvement from -$8.28 million in the previous period[22]. - The net cash inflow from financing activities was $51.37 million, a decrease from $219.58 million in the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,659,318,316.24, down 8.92% from the end of the previous year[5]. - The total assets of Shandong Oriental Ocean Technology Co., Ltd. decreased from CNY 1,821,861,787.75 at the beginning of the period to CNY 1,659,318,316.24 at the end of the period, representing a decline of approximately 8.93%[15]. - The company's current assets decreased from CNY 726,152,680.12 to CNY 625,047,207.74, a reduction of about 13.9%[15]. - The total liabilities decreased from CNY 379,993,273.72 to CNY 324,171,966.56, a decline of about 14.7%[16]. - The company's total equity decreased from CNY 1,441,868,514.03 to CNY 1,335,146,349.68, a reduction of approximately 7.4%[16]. Shareholder Information - The equity attributable to shareholders decreased by 7.37% to ¥1,326,023,397.36 compared to the previous year-end[5]. - The total number of ordinary shareholders at the end of the reporting period was 72,503[10]. Inventory and Receivables - The inventory increased from CNY 220,092,916.76 to CNY 256,585,816.53, reflecting a growth of approximately 16.6%[15]. - The accounts receivable increased from CNY 75,195,699.15 to CNY 79,646,848.69, an increase of about 5.8%[15]. Government Support - The company received government subsidies amounting to ¥2,640,531.29 during the reporting period[6]. Earnings and Losses - The company's gross profit margin declined significantly, primarily due to a 62.56% drop in sea cucumber revenue and a 76.13% decrease in testing and reagent kit revenue[9]. - The retained earnings showed a negative balance, increasing from CNY -2,528,852,997.48 to CNY -2,634,256,073.40, indicating a further loss[16].

证券代码：002086 证券简称：东方海洋 公告编号：2025-058 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的全量程 C—反应蛋白(hSCRP+CRP)测定试剂盒（荧光免 疫层析法）于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册 证，具体情况如下： 一、产品信息 1、全量程 C—反应蛋白(hSCRP+CRP)测定试剂盒（荧光免疫层析法） | 产品名称 | 全量程 C—反应蛋白(hSCRP+CRP)测定试剂盒（荧光免疫层析法） | | | | | | --- | --- | --- | --- | --- | --- | | 注册证编号 | 鲁械注准 20252400655 | | | | | | 注册人名称 | 艾维可生 ...